

Please see the coverage summary for April 2024 new codes below:

Not covered experimental and investigational for ACO, Commercial/ASO:

A2026	Restrata minimatrix, 5 mg
A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each
A4564	Pessary, disposable, any type
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each
C9796	Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])
C9797	Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction
E0736	Transcutaneous tibial nerve stimulator
E0738	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories
Q4305	American amnion ac tri-layer, per square centimeter
Q4306	American amnion ac, per square centimeter
Q4307	American amnion, per square centimeter
Q4308	Sanopellis, per square centimeter
Q4309	Via matrix, per square centimeter
Q4310	Procenta, per 100 mg

Not covered benefit for ACO, Commercial/ASO:

E0152	Walker, battery powered, wheeled, folding, adjustable or fixed height
E0739	Rehab system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors

H0051	Traditional healing service
K1037	Docking station for use with oral device/appliance used to reduce upper airway collapsibility
S4988	Penile contracture device, manual, greater than 3 lbs traction force
S9002	Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device

Prior authorization required for ACO, Commercial/ASO:

E0468	Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions
G0138	Intravenous infusion of cipaglucoisidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucoisidase alfa-atga
L1320	Thoracic, pectus carinatum orthosis, sternal compression, rigid circumferential frame with anterior and posterior rigid pads, custom fabricated
L5783	Addition to lower extremity, user adjustable, mechanical, residual limb volume management system
L5841	Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control

Prior authorization required for ACO, not covered benefit for Commercial/ASO:

E2298	Complex rehabilitative power wheelchair accessory, power seat elevation system, any type
-------	--

No prior authorization required for ACO, Commercial/ASO as preventive service:

A9293	Fertility cycle (contraception & conception) tracking software application, fda cleared, per month, includes accessories (e.g., thermometer)
-------	--

Prior authorization required for Commercial/ASO, not payable for ACO:

0439U	Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD
0440U	Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1], cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD
0444U	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)

0448U	Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes, formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options
0449U	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)

Not covered E/I for Commercial/ASO, not payable for ACO:

0441U	Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index
0442U	Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent
0443U	Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid
0445U	B-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
0446U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity
0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare

Not covered per benefits for ACO:

J0589	Injection, daxibotulinumtoxina-lanm, 1 unit
-------	---

Redirect to Pharmacy for Commercial/ASO:

J1202	Miglustat, oral, 65 mg
J2801	Injection, risperidone (rykindo), 0.5 mg

Redirect to Pharmacy for ACO:

J2801	Injection, risperidone (rykindo), 0.5 mg
-------	--

New to Market not covered unless prior authorized for Commercial/ASO:

C9166	Injection, secukinumab, intravenous, 1 mg
C9167	Injection, apadamtase alfa, 10 units
J0589	Injection, daxibotulinumtoxina-lanm, 1 unit
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5134	Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg

New to Market not covered unless prior authorized for ACO:

C9166	Injection, secukinumab, intravenous, 1 mg
C9167	Injection, apadamtase alfa, 10 units
C9168	Injection, mirikizumab-mrkz, 1 mg
J0177	Injection, aflibercept hd, 1 mg
J1202	Miglustat, oral, 65 mg
J1203	Injection, cipaglucoasidase alfa-atga, 5 mg
J1323	Injection, elranatamab-bcmm, 1 mg
J2277	Injection, motixafortide, 0.25 mg
J2782	Injection, avacincaptad pegol, 0.1 mg
J3055	Injection, talquetamab-tgvs, 0.25 mg
J9376	Injection, pozelimab-bbfg, 1 mg
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5134	Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg

Prior authorization required for Commercial/ASO:

C9168	Injection, mirikizumab-mrkz, 1 mg
J0177	Injection, aflibercept hd, 1 mg
J1203	Injection, cipaglucoasidase alfa-atga, 5 mg
J1323	Injection, elranatamab-bcmm, 1 mg
J2782	Injection, avacincaptad pegol, 0.1 mg
J3055	Injection, talquetamab-tgvs, 0.25 mg
J9376	Injection, pozelimab-bbfg, 1 mg

Prior authorization required for ACO:

J7354	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
-------	--

Prior authorization required for Medicare Advantage:

C9166	Injection, secukinumab, intravenous, 1 mg
C9168	Injection, mirikizumab-mrkz, 1 mg
J0177	Injection, aflibercept hd, 1 mg
J0577	Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
J0578	Injection, buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy
J0589	Injection, daxibotulinumtoxina-lanm, 1 unit
J1203	Injection, cipaglucoasidase alfa-atga, 5 mg
J1323	Injection, elranatamab-bcmm, 1 mg
J2782	Injection, avacincaptad pegol, 0.1 mg
J3055	Injection, talquetamab-tgvs, 0.25 mg

J9376	Injection, pozelimab-bbfg, 1 mg
Q5133	Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg
Q5134	Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg

No prior authorization required for Commercial/ASO:

J0209	Injection, sodium thiosulfate (hope), 100 mg
J0577	Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
J0578	Injection, buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy
J0650	Injection, levothyroxine sodium, not otherwise specified, 10 mcg
J0651	Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to j0650, 10 mcg
J0652	Injection, levothyroxine sodium (hikma) not therapeutically equivalent to j0650, 10 mcg
J1010	Injection, methylprednisolone acetate, 1 mg
J1434	Injection, fosaprepitant (focinvez), 1 mg
J2277	Injection, motixafortide, 0.25 mg
J2919	Injection, methylprednisolone sodium succinate, 5 mg
J3424	Injection, hydroxocobalamin, intravenous, 25 mg
J7165	Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
J7354	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
J9073	Injection, cyclophosphamide (ingenus), 5 mg
J9074	Injection, cyclophosphamide (sandoz), 5 mg
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg
J9248	Injection, melphalan (hepzato), 1 mg

J9249	Injection, melphalan (apotex), 1 mg
-------	-------------------------------------

No prior authorization required for ACO:

J0209	Injection, sodium thiosulfate (hope), 100 mg
J0577	Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
J0578	Injection, buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy
J0650	Injection, levothyroxine sodium, not otherwise specified, 10 mcg
J0651	Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to j0650, 10 mcg
J0652	Injection, levothyroxine sodium (hikma) not therapeutically equivalent to j0650, 10 mcg
J1010	Injection, methylprednisolone acetate, 1 mg
J1434	Injection, fosaprepitant (focinvez), 1 mg
J2919	Injection, methylprednisolone sodium succinate, 5 mg
J3424	Injection, hydroxocobalamin, intravenous, 25 mg
J7165	Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
J9073	Injection, cyclophosphamide (ingenus), 5 mg
J9074	Injection, cyclophosphamide (sandoz), 5 mg
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg
J9248	Injection, melphalan (hepzato), 1 mg
J9249	Injection, melphalan (apotex), 1 mg

No prior authorization required for Medicare Advantage:

C9167	Injection, apadamtase alfa, 10 units
J0209	Injection, sodium thiosulfate (hope), 100 mg

J0650	Injection, levothyroxine sodium, not otherwise specified, 10 mcg
J0651	Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to j0650, 10 mcg
J0652	Injection, levothyroxine sodium (hikma) not therapeutically equivalent to j0650, 10 mcg
J1010	Injection, methylprednisolone acetate, 1 mg
J1434	Injection, fosaprepitant (focinvez), 1 mg
J2277	Injection, motixafortide, 0.25 mg
J2801	Injection, risperidone (rykindo), 0.5 mg
J2919	Injection, methylprednisolone sodium succinate, 5 mg
J3424	Injection, hydroxocobalamin, intravenous, 25 mg
J7165	Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
J7354	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
J9073	Injection, cyclophosphamide (ingenus), 5 mg
J9074	Injection, cyclophosphamide (sandoz), 5 mg
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg
J9248	Injection, melphalan (hepzato), 1 mg
J9249	Injection, melphalan (apotex), 1 mg